Table 2 Prevalence of persistent pain according to detection method, tumor and women’s characteristics

 Age (n = 1045)

0.483

  50–54 (n = 305)

36 (11.8)

  55–59 (n = 281)

37 (13.2)

  60–64 (n = 275)

29 (10.5)

  65–70 (n = 184)

16 (8.7)

 Charlson index (n = 1045)

<0.001

  0 (n = 769)

65 (8.5)

  1 (n = 180)

32 (17.8)

   > =2 (n = 96)

21 (21.9)

  Screen-detected tumors (n = 723)

93 (12.9)

<0.05

  Interval tumors (n = 322)

25 (7.8)

 Tumor size (n = 932)

0.907

   < =10 mm (n = 237)

14 (5.9)

  11 to 20 mm (n = 387)

28 (7.2)

  21 to 50 mm (n = 265)

19 (7.2)

   > 50 mm (n = 43)

2 (4.7)

 Lymph node involvement (n = 1042)

0.564

  Negative (n = 713)

78 (10.9)

  Positive (n = 329)

40 (12.2)

 Number of positive nodes (n = 866)

0.442

   = <3 (n = 781)

54 (6.9)

  4–20 (n = 77)

7 (9.1)

   > 20 (n = 8)

1 (12.5)

 Histological type (n = 1038)

<0.05

  Ductal (n = 763)

94 (12.3)

  In situ (n = 93)

2 (2.2)

  Lobular (n = 98)

14 (14.3)

  Othter (n = 84)

7 (8.3)

 Focality (n = 891)

0.461

  Unifocal (n = 741)

56 (7.6)

  Multifocal and/or multicentric (n = 150)

14 (9.3)

 Histological grade (n = 905)

0.101

  I (n = 228)

19 (8.3)

  II (n = 348)

46 (13.2)

  III (n = 270)

25 (9.3)

  Not applicable (n = 59)

3 (5.1)

 Tumor phenotype (n = 763)

0.291

  Luminal A (n = 404)

41 (10.1)

  Luminal B (n = 207)

12 (5.8)

  HER2 (n = 67)

5 (7.5)

  Triple negative (n = 85)

9 (10.6)